Maria Tsoli

Dr. Maria Tsoli

Children's Cancer Institute, Sydney, Australia
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2014 in Cell Metabolism
Verified
Journal Article
Closed access
MPMichele Petruzzelli
Michele Petruzzelli
MSMartina Schweiger
Martina Schweiger
RSRenate Schreiber
Renate Schreiber
RCRamon Campos-Olivas
Ramon Campos-Olivas
Maria TsoliMaria Tsoli
Maria Tsoli
EWErwin F. Wagner
Erwin F. Wagner

20 July 2005 in Small
Verified
Journal Article
Closed access
PDF file
Maria TsoliMaria Tsoli
Maria Tsoli
HKHubert Kuhn
Hubert Kuhn
WBWolfgang Brandau
Wolfgang Brandau
HEHelmut Esche
Helmut Esche
GSGünter Schmid
Günter Schmid

1 July 2020 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
MCMatthew Clarke
Matthew Clarke
AMAlan Mackay
Alan Mackay
BIBritta Ismer
Britta Ismer
JPJessica Pickles
Jessica Pickles
RTRuth G. Tatevossian
Ruth G. Tatevossian
CJChris Jones
Chris Jones
Infant high-grade gliomas appear clinically distinct from their counterparts in older children, indicating that histopathologic grading may not accurately reflect the biology of these tumors. We have collected 241 cases under 4 years of age, and carried out histologic review, methylation profiling, and custom panel, genome, or exome sequencing. After excluding tumors representing other established entities or subgroups, we identified 130 cases to be part of an “intrinsic” spectrum of disease specific to the infant population. These included those with targetable MAPK alterations, and a large proportion of remaining cases harboring gene fusions targeting ALK (n = 31), NTRK1/2/3 (n = 21), ROS1 (n = 9), and MET (n = 4) as their driving alterations, with evidence of efficacy of targeted agents in the clinic. These data strongly support the concept that infant gliomas require a change in diagnostic practice and management. Significance: Infant high-grade gliomas in the cerebral hemispheres comprise novel subgroups, with a prevalence of ALK, NTRK1/2/3, ROS1, or MET gene fusions. Kinase fusion–positive tumors have better outcome and respond to targeted therapy clinically. Other subgroups have poor outcome, with fusion-negative cases possibly representing an epigenetically driven pluripotent stem cell phenotype. See related video: https://vimeo.com/438254885 See related commentary by Szulzewsky and Cimino, p. 904. This article is highlighted in the In This Issue feature, p. 890

4 January 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
THTammy Hennika
Tammy Hennika
GHGuo Hu
Guo Hu
NONagore G Olaciregui
Nagore G Olaciregui
KBKelly L Barton
Kelly L Barton
AEAnahid Ehteda
Anahid Ehteda
OBOren J Becher
Oren J Becher
Diffuse intrinsic pontine glioma (DIPG), or high-grade brainstem glioma (BSG), is one of the major causes of brain tumor-related deaths in children. Its prognosis has remained poor despite numerous efforts to improve survival. Panobinostat, a histone deacetylase inhibitor, is a targeted agent that has recently shown pre-clinical efficacy and entered a phase I clinical trial for the treatment of children with recurrent or progressive DIPG. A collaborative pre-clinical study was conducted using both a genetic BSG mouse model driven by PDGF-B signaling, p53 loss, and ectopic H3.3-K27M or H3.3-WT expression and an H3.3-K27M orthotopic DIPG xenograft model to confirm and extend previously published findings regarding the efficacy of panobinostat in vitro and in vivo. In vitro, panobinostat potently inhibited cell proliferation, viability, and clonogenicity and induced apoptosis of human and murine DIPG cells. In vivo analyses of tissue after short-term systemic administration of panobinostat to genetically engineered tumor-bearing mice indicated that the drug reached brainstem tumor tissue to a greater extent than normal brain tissue, reduced proliferation of tumor cells and increased levels of H3 acetylation, demonstrating target inhibition. Extended consecutive daily treatment of both genetic and orthotopic xenograft models with 10 or 20 mg/kg panobinostat consistently led to significant toxicity. Reduced, well-tolerated doses of panobinostat, however, did not prolong overall survival compared to vehicle-treated mice. Our collaborative pre-clinical study confirms that panobinostat is an effective targeted agent against DIPG human and murine tumor cells in vitro and in short-term in vivo efficacy studies in mice but does not significantly impact survival of mice bearing H3.3-K27M-mutant tumors. We suggest this may be due to toxicity associated with systemic administration of panobinostat that necessitated dose de-escalation.

30 August 2012 in Cancer Research
Verified
Journal Article
Closed access
PDF file
Maria TsoliMaria Tsoli
Maria Tsoli
MMMelissa Moore
Melissa Moore
DBDominic Burg
Dominic Burg
APArran Painter
Arran Painter
RTRyland Taylor
Ryland Taylor
GRGraham Robertson
Graham Robertson
Cancer cachexia/anorexia is a complex syndrome that involves profound metabolic imbalances and is directly implicated as a cause of death in at least 20% to 30% of all cancers. Brown adipose tissue (BAT) plays a key role in thermogenesis and energy balance and potentially contributes to the physiologic perturbations associated with cachexia. In this study, we investigated the impact of cachexia-inducing colorectal tumor on BAT in mice. We found that brown adipocytes were smaller and exhibited profound delipidation in cachectic tumor–bearing mice. Diurnal expression profiling of key regulators of lipid accumulation and fatty acid β-oxidation and their corresponding target genes revealed dramatic molecular changes indicative of active BAT. Increased Ucp1, Pbe, and Cpt1α expression at specific points coincided with higher BAT temperatures during the dark cycle, suggestive of a temporal stimulation of thermogenesis in cachexia. These changes persisted when cachectic mice were acclimatized to 28°C confirming inappropriate stimulation of BAT despite thermoneutrality. Evidence of inflammatory signaling also was observed in the BAT as an energetically wasteful and maladaptive response to anorexia during the development of cachexia. Cancer Res; 72(17); 4372–82. ©2012 AACR.

1 April 2013 in Trends in Endocrinology & Metabolism
Verified
Journal Article
Closed access
Maria TsoliMaria Tsoli
Maria Tsoli
GRGraham Robertson
Graham Robertson